Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Protocol ID
AOST2032
Disease (Sub Disease)
Osteosarcoma
Diagnosis Stage
Newly diagnosed
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 2/3
Age Eligibility
up to 40 Years
International registry ID's
NCT05691478
| Study Title | A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
|---|---|
| Protocol ID | AOST2032 |
| Disease (Sub Disease) | Osteosarcoma |
| Diagnosis Stage | Newly diagnosed |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT05691478 |
| Trial Status | Preparing to Open |
| Study Type | Treatment |
| Phase | Phase 2/3 |
| Age Eligibility | up to 40 Years |
| International registry ID's | NCT05691478 |